electroCore (NASDAQ:ECOR – Get Free Report) and Teleflex (NYSE:TFX – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.
Profitability
This table compares electroCore and Teleflex’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| electroCore | -33.46% | N/A | -74.21% |
| Teleflex | 13.51% | 10.57% | 4.96% |
Volatility & Risk
electroCore has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Teleflex has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500.
Insider & Institutional Ownership
26.7% of electroCore shares are owned by institutional investors. Comparatively, 95.6% of Teleflex shares are owned by institutional investors. 7.8% of electroCore shares are owned by insiders. Comparatively, 0.7% of Teleflex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares electroCore and Teleflex”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| electroCore | $32.03 million | 2.04 | -$13.97 million | ($1.66) | -4.37 |
| Teleflex | $1.99 billion | 3.21 | -$905.64 million | ($23.29) | -6.48 |
electroCore has higher earnings, but lower revenue than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than electroCore, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for electroCore and Teleflex, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| electroCore | 1 | 1 | 1 | 0 | 2.00 |
| Teleflex | 1 | 5 | 5 | 1 | 2.50 |
electroCore presently has a consensus target price of $18.00, indicating a potential upside of 148.28%. Teleflex has a consensus target price of $160.80, indicating a potential upside of 6.57%. Given electroCore’s higher probable upside, equities research analysts clearly believe electroCore is more favorable than Teleflex.
Summary
Teleflex beats electroCore on 10 of the 15 factors compared between the two stocks.
About electroCore
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
About Teleflex
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
